People with FSHD, ages 16 to 70, enrolled in this Phase 1/2 FORTITUDE trial cohort will aid biomarker data to support early approval request.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback